[Home]   [Full version]  

Crucial progress in understanding Fragile X mental retardation protein

Jun 06 ,Medicine & Health


Researchers in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine have identified a new regulatory target for the Fragile X mental retardation protein (FMRP), laying the groundwork for possible new treatments for Fragile X syndrome(FXS), the leading inherited form of mental retardation.

The findings, published in the early online edition of the June Proceedings of the National Academy of Sciences, also have implications for autism, which shares a common physiological pathway with FXS.

Fragile X syndrome is mainly caused by a mutation in the FMR1 gene on the X chromosome, leading to the loss of FMRP, which is abundantly expressed in the brain and testes. Without this protein, brain development is hampered and nerve cells cannot communicate with each other appropriately, resulting in the reduced ability to learn and memorize. Fragile X syndrome affects about one in 4,000 males and one in 8,000 females. About 20 percent of children with FXS have autism and about five percent of autistic children have FXS.

The research team led by Yingqun Huang, M.D., assistant professor in Yale Ob/Gyn, previously found that FMRP interacts with a nuclear mRNA export protein NXF2, in the mouse brain and testes. In this study, the team used mouse neuronal cells to explore the functional characteristics of this interaction.

“We found that FMRP, together with NXF2, acts to down-regulate the expression of its target, the messenger RNA that encodes NXF1, which is an essential protein needed to transport most mRNAs from the nucleus to the cytoplasm of cells,” said Huang. “Our findings explain why the NXF1 protein level is much lower in the hippocampal neurons involved in learning and memory than in many other cells. This may suggest that a high level of NXF1 might hinder the function of these cells.”

“We are one of the first two labs to show that FMRP regulates gene expression at the mRNA stability level,” Huang added. “The idea is to find the mechanisms underlying the function of FMRP so in the future, we can develop more effective interventions.”

Huang said future studies will look more closely at how FMRP works with NXF2 to regulate its targets. She said, “We expect to identify more targets which are regulated by FMRP and NXF2. This will be a new direction in the FMRP research field.”

Source: Yale University

Related stories:

Mechanism may explain aspects of brain impairment seen in Fragile X Syndrome
Scientists report that a protein associated with a common form of mental retardation plays an important role in intracellular trafficking within neurons. The research, published by Cell Press in the June issue of the journal Developmental Cell, reveals new information about how neuronal communication and plasticity are affected in Fragile X Syndrome (FXS).
Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
Scientists using a new drug screening method in Drosophila (fruit flies), have identified several drugs and small molecules that reverse the features of fragile X syndrome -- a frequent form of mental retardation and one of the leading known causes of autism. The discovery sets the stage for developing new treatments for fragile X syndrome.
Fragile X retardation syndrome corrected in mice
Researchers working with mice have significantly alleviated a wide range of abnormalities due to fragile X syndrome by altering only a single gene, countering the effects of the fragile X mutation. They said their achievement offers the potential for treatment of the disorder, the most common form of inherited mental retardation and a leading identified genetic cause of autism. There is currently no treatment or therapy for fragile X syndrome, whose symptoms include mental retardation, epilepsy, and abnormal body growth.
Scientists identify fundamental brain defect, probable drug target in fragile X syndrome
Scientists have discovered how the gene mutation responsible for fragile X syndrome--the most common inherited form of mental retardation--alters the way brain cells communicate. In neurons cultured from laboratory rats, the scientists also were able to reverse the effects of the mutation using a drug targeted to the specific site in an upstream pathway of the defect. The finding could lead to the development of human therapies for this previously untreatable condition.
Stem cell research produces a key discovery for Fragile X Syndrome
An important finding has been made by McMaster researchers about Fragile X Syndrome (FXS), a sex-linked genetic disorder that affects approximately one in 4,000 males and one in 6,000 females.

News discussion:

Medicine & Health news

[Home]   [Full version]